GCG and Alzheimer disease: Research conducted by D'Amico et al. evaluating the use of sitagliptin in AD mice indicated increased concentration of GLP-1 in the encephalon area and a noticeable (approximately 60%) decrease of βAPP and Aβ residue accumulation within hippocampus area of mice after administration of sitagliptin in comparison with mice not treated with the drug.